Publications by authors named "M T Zenner"
Prostate cancer is the second leading cause of malignancy-related deaths among American men. Active surveillance is a safe option for many men with less aggressive disease, yet definitively determining low-risk cancer is challenging with biopsy alone. Herein, we sought to identify prostate-derived microRNAs in patient sera and serum extracellular vesicles, and determine if those microRNAs improve upon the current clinical risk calculators for prostate cancer prognosis before and after biopsy.
View Article and Find Full Text PDFProstate cancer is the second leading cause of malignancy-related deaths among American men. Active surveillance is a safe option for many men with less aggressive disease, yet definitively determining low-risk cancer is challenging with biopsy alone. Herein, we sought to identify prostate-derived microRNAs in patient sera and serum extracellular vesicles, and determine if those microRNAs improve upon the current clinical risk calculators for prostate cancer prognosis before and after biopsy.
View Article and Find Full Text PDFArticle Synopsis
- - Benign prostate hyperplasia and prostate cancer both involve excessive growth of prostate tissue, highlighting the need to understand the normal progenitor cells in the prostate and identify potential drug targets.
- - Researchers used single-cell RNA sequencing (scRNA-Seq) to identify a specific population of luminal progenitor cells in the prostate of mice, both with and without hormonal treatment.
- - The study found key factors essential for regenerating prostate organoids from mice and humans, suggesting scRNA-Seq can help uncover potential pharmacologic strategies aimed at the cell populations responsible for prostate diseases.
Background: The metabolism of normal prostate relies on glycolysis, with prostate cancer having reduced glycolysis and increased aerobic metabolism. Advanced glycation end products (AGEs) accumulate in tissues as a result of age and glycolytic rate. Differential AGE levels were recently observed in prostate cancer tissues.
View Article and Find Full Text PDFOncogenic and tumor-suppressive microRNAs in prostate cancer.
Curr Opin Endocr Metab Res
February 2020
MicroRNAs are known to be dysregulated in prostate cancer. These small noncoding RNAs can function as biomarkers and are involved in the biology of prostate cancer. The canonical mechanism for microRNAs is post-transcription regulation of gene expression via binding to the 3' untranslated region of mRNAs, resulting in RNA degradation and/or translational repression.
View Article and Find Full Text PDF